Omeros Corporation

4.17 USD
+0.20 (+5.04%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Omeros Corporation stock is up 26.75% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 14 June’s closed higher than May. 0% of analysts rate it a buy.

About Omeros Corporation

Omeros Corporation discovers, develops, and commercializes small-molecule and protein therapeutics. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and atypical hemolytic uremic syndrome (aHUS) The company was incorporated in 1994 and headquartered in Seattle, Washington.